Axovant's Cupboard Is Bare After Lead Dementia Program Fails
'New year, new me' is a mantra to be adopted by Swiss drug developer Axovant as it seeks new products to fill its pipeline. The CNS-focused company is floundering having ended development of its lead compound intepirdine following another clinical trial failure.
You may also be interested in...
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.
Axovant was Roivant's star and the first test of its risk-reducing strategy, but the company will attempt to move its spotlight to other assets at an R&D day on July 10. Ahead of the event, Roivant announced a reorganization to strengthen its subsidiaries and accelerate the creation of new ones.